Randomised trial of monoclonal antibody for adjuvant therapy of resected Dukes' C colorectal carcinoma. German Cancer Aid 17-1A Study Group (Q34322325)

1 August 2017

title

Randomised trial of monoclonal antibody for adjuvant therapy of resected Dukes' C colorectal carcinoma. German Cancer Aid 17-1A Study Group (English)

1 reference

1 August 2017

1 reference

1 reference

G Riethmüller

1

1 reference

1 August 2017

E Schneider-Gädicke

2

1 reference

1 August 2017

G Schlimok

3

1 reference

1 August 2017

W Schmiegel

4

1 reference

1 August 2017

R Raab

5

1 reference

1 August 2017

K Höffken

6

1 reference

1 August 2017

R Gruber

7

1 reference

1 August 2017

H Pichlmaier

8

1 reference

1 August 2017

H Hirche

9

1 reference

1 August 2017

R Pichlmayr

10

1 reference

1 August 2017

language of work or name

English

0 references

publication date

1 May 1994

1 reference

1 August 2017

1 reference

1 August 2017

volume

343

1 reference

1 August 2017

issue

8907

1 reference

1 August 2017

page(s)

1177-1183

1 reference

Clinical perspective of human colorectal cancer metastasis

1 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2894%2992398-1

7 January 2021

Monoclonal antibodies in the detection and therapy of micrometastatic epithelial cancers

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2894%2992398-1

7 January 2021

Prognostic significance of micrometastatic tumour cells in bone marrow of colorectal cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2894%2992398-1

7 January 2021

Colorectal carcinoma-specific antigen: detection by means of monoclonal antibodies

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2894%2992398-1

7 January 2021

Colorectal carcinoma antigens detected by hybridoma antibodies

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2894%2992398-1

7 January 2021

The epithelial cell surface antigen 17-1A, a target for antibody-mediated tumor therapy: its biochemical nature, tissue distribution and recognition by different monoclonal antibodies

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2894%2992398-1

7 January 2021

Molecular cloning of cDNA for the carcinoma-associated antigen GA733-2.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2894%2992398-1

7 January 2021

Epithelial glycoprotein is a member of a family of epithelial cell surface antigens homologous to nidogen, a matrix adhesion protein

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2894%2992398-1

7 January 2021

The randomization and stratification of patients to clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2894%2992398-1

7 January 2021

A New Design for Randomized Clinical Trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2894%2992398-1

7 January 2021

Effective surgical adjuvant therapy for high-risk rectal carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2894%2992398-1

7 January 2021

Postoperative adjuvant chemotherapy or radiation therapy for rectal cancer: results from NSABP protocol R-01

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2894%2992398-1

7 January 2021

Current applications of monoclonal antibodies for the therapy of hematopoietic cancers

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2894%2992398-1

7 January 2021

Patients receiving murine monoclonal antibody therapy for malignancy develop T cells that proliferate in vitro in response to these antibodies as antigens

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2894%2992398-1

7 January 2021

Antibodies as antigens. The use of mouse monoclonal antibodies to focus human T cells against selected targets.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2894%2992398-1

7 January 2021

IgG2a monoclonal antibodies inhibit human tumor growth through interaction with effector cells

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2894%2992398-1

7 January 2021

Tumour-growth suppression in nude mice by a murine monoclonal antibody: Factors hampering successful therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2894%2992398-1

7 January 2021

Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2894%2992398-1

7 January 2021

Micrometastatic tumour cells in bone marrow in colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2894%2992398-1

7 January 2021

Differential Expression of Proliferation-Associated Molecules in Individual Micrometastatic Carcinoma Cells

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2894%2992398-1

7 January 2021

https://api.crossref.org/works/10.1016%2FS0140-6736%2894%2992398-1

1 reference

7 January 2021

Mouse/human chimeric monoclonal antibody in man: kinetics and immune response

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2894%2992398-1

7 January 2021

Continuous cultures of fused cells secreting antibody of predefined specificity

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2894%2992398-1

7 January 2021

10.1016/S0140-6736(94)92398-1

Identifiers

DOI

1 reference

1 August 2017

1 reference